Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory Disease
Introduction Despite the use of unfractionated heparin (UFH) or low molecular weight heparin (LMWH), rates of thromboembolic disease, and subsequent morbidity and mortality remain unacceptably high in patients with severe novel coronavirus disease 2019 (COVID-19) disease. Direct oral anticoagulants...
Main Authors: | Eric Wenzler, Monaz H. Engineer, Maidah Yaqoob, Scott T. Benken |
---|---|
Format: | Article |
Language: | English |
Published: |
Georg Thieme Verlag KG
2020-10-01
|
Series: | TH Open |
Subjects: | |
Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1720962 |
Similar Items
-
Idiopathic pulmonary vein thrombosis treated with apixaban
by: Dallis Ngo, et al.
Published: (2021-08-01) -
Development of Pacemaker Lead Thrombosis in a Patient with Atrial Fibrillation during Apixaban Treatment
by: Adem Adar, et al.
Published: (2019-10-01) -
Traumatic Pseudoaneursym of Superficial Temporal Artery in an Octogenarian Patient Under Apixaban Therapy
by: Sertan Özyalçın, et al.
Published: (2020-02-01) -
ORAL ANTICOAGULANTS IN THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS: FOCUS ON APIXABAN
by: M. Yu. Gilyarov, et al.
Published: (2017-12-01) -
A review of pharmacogenetics of anticoagulant therapy: Heparins, rivaroxaban, apixaban, and dabigatran
by: Ali Mohammed Abd Alridha, et al.
Published: (2022-01-01)